ACAD vs MRNA · P/E 15, rev $576.0M vs rev $145.0M
ACADIA Pharmaceuticals Inc (ACAD) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the ACAD and MRNA stock pages for the full models.
Not investment advice.